The iconic rise of Sildenafil presented a massive chance for shareholders , but its patent has lapsed , creating a challenging landscape. Alternative versions have flooded the arena, cutting into sales and putting a squeeze on profit yields. While leading healthcare companies hold a foothold in this area, the potential remains ambiguous by fierce c